Biotech Values

[BTH]

re: MARQUEE

This recent data, I would say, that points to the utility of the tivantinib combination with erlotinib in a subset of the population that was selected originally. And originally, we selected a patient population than what is logically defined as non-squamous cell, advance non-small cell. The trial was second line and third line. We will report later on what the balance of the patients was between second-line and third-line therapy as well. And hopefully, we will be in the position to provide as much data as we will to be able to collect about post-treatment therapies whether deviations had been second-line treated or third-line treated. So that data is quite challenging to collect, as you all know. We are encouraged by this analysis. But at this time, we do not believe that this analysis give us an opportunity to redefine regulatory process for this trial at least in the Western world.